Extract
Lung volume reduction has led to substantial benefits for well-selected patients with advanced emphysema associated with lung hyperinflation and with persistent disabling symptoms despite optimised medical therapy. Recently, following US Food and Drug Administration (FDA) and European Medicines Agency approval, endobronchial valve (EBV) treatment has largely replaced lung volume reduction surgery (LVRS) as the preferred initial approach to volume reduction. EBVs induce volume reduction through partial or complete lobar atelectasis, without the burden of chest wall incision and lung resection [1, 2]. While several randomised trials have reported clinically important improvements in lung function, symptoms and functional performance, but >34% rate of pneumothorax following EBV [3–5], no randomised clinical trial has directly compared the benefits and risks of LVRS to EBVs until today.
Abstract
The comparison between LVRS and EBV can provide guidance with respect to the clinical decision-making process in the treatment of individuals with advanced emphysema https://bit.ly/3mHHzUU
Footnotes
Conflict of interest: F. Polverino reports unrestricted grant funds from Boehringer Ingelheim, lecture honoraria from University of California San Francisco and Emory University, travel support from FWO Flanders, holds a leadership role with ATS RCMB executive committee, and is a section editor for the European Respiratory Journal, outside the submitted work. F. Sciurba reports institutional grant support from Pulmonx, outside the submitted work.
- Received March 1, 2023.
- Accepted March 6, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org